eurofins genomics uk limited
eurofins genomics uk limited Company Information
Company Number
03297407
Next Accounts
Sep 2025
Shareholders
eurofins genomics lux holding sarl
Group Structure
View All
Industry
Technical testing and analysis
Registered Address
i54 busines park, valiant way, wolverhampton, WV9 5GB
Website
www.eurofinsgenomics.eueurofins genomics uk limited Estimated Valuation
Pomanda estimates the enterprise value of EUROFINS GENOMICS UK LIMITED at £3m based on a Turnover of £4.3m and 0.7x industry multiple (adjusted for size and gross margin).
eurofins genomics uk limited Estimated Valuation
Pomanda estimates the enterprise value of EUROFINS GENOMICS UK LIMITED at £1.5m based on an EBITDA of £321k and a 4.78x industry multiple (adjusted for size and gross margin).
eurofins genomics uk limited Estimated Valuation
Pomanda estimates the enterprise value of EUROFINS GENOMICS UK LIMITED at £2.5m based on Net Assets of £1m and 2.39x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Eurofins Genomics Uk Limited Overview
Eurofins Genomics Uk Limited is a live company located in wolverhampton, WV9 5GB with a Companies House number of 03297407. It operates in the technical testing and analysis sector, SIC Code 71200. Founded in December 1996, it's largest shareholder is eurofins genomics lux holding sarl with a 100% stake. Eurofins Genomics Uk Limited is a mature, small sized company, Pomanda has estimated its turnover at £4.3m with declining growth in recent years.
Upgrade for unlimited company reports & a free credit check
Eurofins Genomics Uk Limited Health Check
Pomanda's financial health check has awarded Eurofins Genomics Uk Limited a 3 rating. We use a traffic light system to show it exceeds the industry average on 2 measures and has 6 areas for improvement. Company Health Check FAQs
2 Strong
3 Regular
6 Weak
Size
annual sales of £4.3m, make it in line with the average company (£5.3m)
£4.3m - Eurofins Genomics Uk Limited
£5.3m - Industry AVG
Growth
3 year (CAGR) sales growth of -13%, show it is growing at a slower rate (4.5%)
-13% - Eurofins Genomics Uk Limited
4.5% - Industry AVG
Production
with a gross margin of 28.9%, this company has a higher cost of product (43.7%)
28.9% - Eurofins Genomics Uk Limited
43.7% - Industry AVG
Profitability
an operating margin of 6.9% make it more profitable than the average company (4.5%)
6.9% - Eurofins Genomics Uk Limited
4.5% - Industry AVG
Employees
with 8 employees, this is below the industry average (40)
8 - Eurofins Genomics Uk Limited
40 - Industry AVG
Pay Structure
on an average salary of £49.5k, the company has an equivalent pay structure (£46.3k)
£49.5k - Eurofins Genomics Uk Limited
£46.3k - Industry AVG
Efficiency
resulting in sales per employee of £536.9k, this is more efficient (£108.9k)
£536.9k - Eurofins Genomics Uk Limited
£108.9k - Industry AVG
Debtor Days
it gets paid by customers after 63 days, this is near the average (58 days)
63 days - Eurofins Genomics Uk Limited
58 days - Industry AVG
Creditor Days
its suppliers are paid after 7 days, this is quicker than average (28 days)
7 days - Eurofins Genomics Uk Limited
28 days - Industry AVG
Stock Days
There is insufficient data available for this Key Performance Indicator!
- - Eurofins Genomics Uk Limited
- - Industry AVG
Cash Balance
has cash to cover current liabilities for 8 weeks, this is less cash available to meet short term requirements (13 weeks)
8 weeks - Eurofins Genomics Uk Limited
13 weeks - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 76.8%, this is a higher level of debt than the average (58.9%)
76.8% - Eurofins Genomics Uk Limited
58.9% - Industry AVG
EUROFINS GENOMICS UK LIMITED financials
Eurofins Genomics Uk Limited's latest turnover from December 2023 is £4.3 million and the company has net assets of £1 million. According to their latest financial statements, Eurofins Genomics Uk Limited has 8 employees and maintains cash reserves of £580 thousand as reported in the balance sheet.
Data source: Companies House, Pomanda Estimates
| Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Turnover | 4,295,000 | 6,740,000 | 8,656,000 | 6,557,000 | 7,297,000 | 5,976,000 | 6,695,152 | 7,021,974 | 4,686,294 | 4,195,345 | 3,942,153 | 3,641,742 | 3,393,192 | 3,803,638 | 3,982,406 |
| Other Income Or Grants | |||||||||||||||
| Cost Of Sales | 3,055,000 | 5,753,000 | 7,183,000 | 5,129,000 | 5,366,000 | 4,293,000 | 4,866,878 | 4,880,619 | 2,878,608 | 2,774,048 | 2,671,273 | 2,390,374 | 2,414,810 | 2,692,302 | 2,955,939 |
| Gross Profit | 1,240,000 | 987,000 | 1,473,000 | 1,428,000 | 1,931,000 | 1,683,000 | 1,828,274 | 2,141,355 | 1,807,686 | 1,421,297 | 1,270,880 | 1,251,368 | 978,382 | 1,111,336 | 1,026,467 |
| Admin Expenses | 945,000 | 1,476,000 | 1,834,000 | 663,000 | 2,328,000 | 1,363,000 | 1,225,725 | 1,203,102 | 921,018 | 893,934 | 840,234 | 691,225 | 600,837 | -60,074 | 2,010,962 |
| Operating Profit | 295,000 | -489,000 | -361,000 | 765,000 | -397,000 | 320,000 | 602,549 | 938,253 | 886,668 | 527,363 | 430,646 | 560,143 | 377,545 | 1,171,410 | -984,495 |
| Interest Payable | 3,000 | 12,000 | 3,000 | 25,000 | 5,000 | 183 | 61 | 9 | 3,788 | 9,007 | 37,470 | 37,290 | 45,498 | ||
| Interest Receivable | 10,000 | 4,000 | 1,000 | 7,000 | 665 | ||||||||||
| Pre-Tax Profit | 302,000 | -497,000 | -364,000 | 740,000 | -401,000 | 327,000 | 603,214 | 938,070 | 886,607 | 527,354 | 426,858 | 551,136 | 340,075 | 1,134,120 | -1,029,993 |
| Tax | 111,000 | -4,000 | 22,000 | -21,000 | |||||||||||
| Profit After Tax | 413,000 | -501,000 | -342,000 | 740,000 | -401,000 | 306,000 | 603,214 | 938,070 | 886,607 | 527,354 | 426,858 | 551,136 | 340,075 | 1,134,120 | -1,029,993 |
| Dividends Paid | 306,000 | 1,600,000 | 650,000 | 1,340,000 | 250,000 | 850,000 | |||||||||
| Retained Profit | 413,000 | -501,000 | -342,000 | 434,000 | -2,001,000 | 306,000 | 603,214 | 288,070 | -453,393 | 277,354 | -423,142 | 551,136 | 340,075 | 1,134,120 | -1,029,993 |
| Employee Costs | 396,000 | 1,110,000 | 1,165,000 | 854,000 | 1,068,000 | 865,000 | 781,307 | 797,474 | 608,719 | 575,504 | 529,735 | 427,323 | 379,361 | 651,113 | 972,097 |
| Number Of Employees | 8 | 15 | 16 | 16 | 17 | 16 | 14 | 16 | 12 | 12 | 11 | 9 | 9 | 11 | 18 |
| EBITDA* | 321,000 | -453,000 | -321,000 | 797,000 | -374,000 | 341,000 | 602,655 | 939,468 | 888,411 | 530,155 | 449,286 | 578,198 | 394,580 | 1,197,622 | -792,045 |
* Earnings Before Interest, Tax, Depreciation and Amortisation
| Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tangible Assets | 44,000 | 66,000 | 106,000 | 72,000 | 26,000 | 106 | 1,321 | 3,064 | 4,916 | 2,959 | 1,852 | 85 | 97,156 | ||
| Intangible Assets | 2,876,000 | 2,876,000 | 2,876,000 | 2,876,000 | 2,876,000 | 251,000 | 250,764 | 250,764 | 250,764 | 250,764 | 250,764 | 267,481 | 284,198 | 300,915 | 317,632 |
| Investments & Other | |||||||||||||||
| Debtors (Due After 1 year) | 140,000 | 31,000 | 22,000 | ||||||||||||
| Total Fixed Assets | 3,060,000 | 2,973,000 | 3,004,000 | 2,948,000 | 2,902,000 | 251,000 | 250,764 | 250,870 | 252,085 | 253,828 | 255,680 | 270,440 | 286,050 | 301,000 | 414,788 |
| Stock & work in progress | 1,865 | ||||||||||||||
| Trade Debtors | 743,000 | 1,291,000 | 1,885,000 | 1,296,000 | 954,000 | 1,329,000 | 1,008,373 | 1,377,750 | 775,721 | 673,682 | 628,879 | 537,516 | 504,671 | 517,970 | 574,566 |
| Group Debtors | 57,000 | 2,000 | 26,000 | 1,000 | 98,000 | 802,000 | 801,429 | 1,116 | 16,086 | 8 | 1,731 | 509 | 6,774 | 20,685 | 104 |
| Misc Debtors | 6,000 | 85,000 | 234,000 | 39,000 | 786,000 | 567,000 | 91,136 | 47,055 | 22,541 | 36,014 | 20,993 | 15,370 | 37,277 | 130,187 | 78,168 |
| Cash | 580,000 | 271,000 | 967,000 | 1,917,000 | 2,905,000 | 86,000 | 456,986 | 493,364 | 414,611 | 797,243 | 370,131 | 1,148,162 | 337,449 | 70,592 | |
| misc current assets | |||||||||||||||
| total current assets | 1,386,000 | 1,649,000 | 3,112,000 | 3,253,000 | 4,743,000 | 2,784,000 | 2,357,924 | 1,919,285 | 1,228,959 | 1,506,947 | 1,021,734 | 1,701,557 | 886,171 | 739,434 | 654,703 |
| total assets | 4,446,000 | 4,622,000 | 6,116,000 | 6,201,000 | 7,645,000 | 3,035,000 | 2,608,688 | 2,170,155 | 1,481,044 | 1,760,775 | 1,277,414 | 1,971,997 | 1,172,221 | 1,040,434 | 1,069,491 |
| Bank overdraft | 176,071 | ||||||||||||||
| Bank loan | |||||||||||||||
| Trade Creditors | 65,000 | 104,000 | 287,000 | 17,000 | 7,000 | 3,000 | 1,496,531 | 11,888 | 30,653 | 47,635 | 21,985 | 8,850 | 2,384 | 5,936 | 15,682 |
| Group/Directors Accounts | 334,000 | 684,000 | 1,316,000 | 876,000 | 464,000 | 352,000 | 177,649 | 431,553 | 433,607 | 1,104,531 | 2,249,599 | ||||
| other short term finances | |||||||||||||||
| hp & lease commitments | 11,000 | 42,000 | 13,000 | 18,000 | 21,000 | 1,341 | 3,129 | ||||||||
| other current liabilities | 2,978,000 | 3,892,000 | 4,027,000 | 3,754,000 | 6,122,000 | 1,257,000 | 1,653,728 | 1,237,391 | 1,047,685 | 689,679 | 720,351 | 476,123 | 658,594 | 489,098 | |
| total current liabilities | 3,388,000 | 4,722,000 | 5,643,000 | 4,665,000 | 6,614,000 | 1,612,000 | 1,496,531 | 1,665,616 | 1,268,044 | 1,095,320 | 889,313 | 1,160,754 | 912,114 | 1,770,402 | 2,933,579 |
| loans | |||||||||||||||
| hp & lease commitments | 28,000 | 12,000 | 92,000 | 53,000 | 5,000 | ||||||||||
| Accruals and Deferred Income | |||||||||||||||
| other liabilities | 3,000 | 3,000 | 3,000 | ||||||||||||
| provisions | 16,000 | ||||||||||||||
| total long term liabilities | 28,000 | 12,000 | 95,000 | 72,000 | 8,000 | ||||||||||
| total liabilities | 3,416,000 | 4,734,000 | 5,738,000 | 4,737,000 | 6,622,000 | 1,612,000 | 1,496,531 | 1,665,616 | 1,268,044 | 1,095,320 | 889,313 | 1,160,754 | 912,114 | 1,770,402 | 2,933,579 |
| net assets | 1,030,000 | -112,000 | 378,000 | 1,464,000 | 1,023,000 | 1,423,000 | 1,112,157 | 504,539 | 213,000 | 665,455 | 388,101 | 811,243 | 260,107 | -729,968 | -1,864,088 |
| total shareholders funds | 1,030,000 | -112,000 | 378,000 | 1,464,000 | 1,023,000 | 1,423,000 | 1,112,157 | 504,539 | 213,000 | 665,455 | 388,101 | 811,243 | 260,107 | -729,968 | -1,864,088 |
| Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | |||||||||||||||
| Operating Profit | 295,000 | -489,000 | -361,000 | 765,000 | -397,000 | 320,000 | 602,549 | 938,253 | 886,668 | 527,363 | 430,646 | 560,143 | 377,545 | 1,171,410 | -984,495 |
| Depreciation | 26,000 | 36,000 | 40,000 | 32,000 | 23,000 | 21,000 | 106 | 1,215 | 1,743 | 2,792 | 1,923 | 1,338 | 318 | 9,495 | 175,733 |
| Amortisation | 16,717 | 16,717 | 16,717 | 16,717 | 16,717 | ||||||||||
| Tax | 111,000 | -4,000 | 22,000 | -21,000 | |||||||||||
| Stock | -1,865 | 1,865 | |||||||||||||
| Debtors | -463,000 | -758,000 | 831,000 | -502,000 | -860,000 | 797,062 | 475,017 | 611,573 | 104,644 | 58,101 | 98,208 | 4,673 | -120,120 | 16,004 | 652,838 |
| Creditors | -39,000 | -183,000 | 270,000 | 10,000 | 4,000 | -1,493,531 | 1,484,643 | -18,765 | -16,982 | 25,650 | 13,135 | 6,466 | -3,552 | -9,746 | 15,682 |
| Accruals and Deferred Income | -914,000 | -135,000 | 273,000 | -2,368,000 | 4,865,000 | 1,257,000 | -1,653,728 | 416,337 | 189,706 | 358,006 | -30,672 | 244,228 | -182,471 | 169,496 | 489,098 |
| Deferred Taxes & Provisions | -16,000 | 16,000 | |||||||||||||
| Cash flow from operations | -58,000 | -17,000 | -603,000 | -1,043,000 | 5,355,000 | -713,593 | -41,447 | 725,467 | 956,491 | 855,710 | 333,541 | 824,219 | 328,677 | 1,343,233 | -941,968 |
| Investing Activities | |||||||||||||||
| capital expenditure | |||||||||||||||
| Change in Investments | |||||||||||||||
| cash flow from investments | |||||||||||||||
| Financing Activities | |||||||||||||||
| Bank loans | |||||||||||||||
| Group/Directors Accounts | -350,000 | -632,000 | 440,000 | 412,000 | 112,000 | 352,000 | -177,649 | -253,904 | -2,054 | -670,924 | -1,145,068 | 2,249,599 | |||
| Other Short Term Loans | |||||||||||||||
| Long term loans | |||||||||||||||
| Hire Purchase and Lease Commitments | -15,000 | -51,000 | 34,000 | 45,000 | 26,000 | -1,341 | -1,788 | 3,129 | |||||||
| other long term liabilities | -3,000 | 3,000 | |||||||||||||
| share issue | |||||||||||||||
| interest | 7,000 | -8,000 | -3,000 | -25,000 | -4,000 | 7,000 | 665 | -183 | -61 | -9 | -3,788 | -9,007 | -37,470 | -37,290 | -45,498 |
| cash flow from financing | 371,000 | -683,000 | -273,000 | 439,000 | 1,738,000 | 363,843 | 5,069 | 3,286 | 877 | -177,658 | -257,692 | -11,061 | -59,735 | -1,184,146 | 1,373,135 |
| cash and cash equivalents | |||||||||||||||
| cash | 309,000 | -696,000 | -950,000 | -988,000 | 2,819,000 | -370,986 | -36,378 | 78,753 | -382,632 | 427,112 | -778,031 | 810,713 | 266,857 | 70,592 | |
| overdraft | -176,071 | 176,071 | |||||||||||||
| change in cash | 309,000 | -696,000 | -950,000 | -988,000 | 2,819,000 | -370,986 | -36,378 | 78,753 | -382,632 | 427,112 | -778,031 | 810,713 | 266,857 | 246,663 | -176,071 |
eurofins genomics uk limited Credit Report and Business Information
Eurofins Genomics Uk Limited Competitor Analysis
Perform a competitor analysis for eurofins genomics uk limited by selecting its closest rivals, whether from the PROFESSIONAL, SCIENTIFIC AND TECHNICAL ACTIVITIES sector, other small companies, companies in WV9 area or any other competitors across 12 key performance metrics.
eurofins genomics uk limited Ownership
EUROFINS GENOMICS UK LIMITED group structure
Eurofins Genomics Uk Limited has no subsidiary companies.
Ultimate parent company
EUROFINS SCIENTIFIC SE
#0061455
EUROFINS GENOMICS LUX HOLDING SARL
#0060235
2 parents
EUROFINS GENOMICS UK LIMITED
03297407
eurofins genomics uk limited directors
Eurofins Genomics Uk Limited currently has 2 directors. The longest serving directors include Dr Josiane Chuisseu Wandji (Nov 2021) and Mr Michael Watts (Apr 2023).
| officer | country | age | start | end | role |
|---|---|---|---|---|---|
| Dr Josiane Chuisseu Wandji | England | 45 years | Nov 2021 | - | Director |
| Mr Michael Watts | 56 years | Apr 2023 | - | Director |
P&L
December 2023turnover
4.3m
-36%
operating profit
295k
-160%
gross margin
28.9%
+97.15%
turnover
Turnover, or revenue, is the amount of sales generated by a company within the financial year.
Balance Sheet
December 2023net assets
1m
-10.2%
total assets
4.4m
-0.04%
cash
580k
+1.14%
net assets
Total assets minus all liabilities
eurofins genomics uk limited company details
company number
03297407
Type
Private limited with Share Capital
industry
71200 - Technical testing and analysis
incorporation date
December 1996
age
29
incorporated
UK
ultimate parent company
accounts
Small Company
last accounts submitted
December 2023
previous names
eurofins genetic services limited (January 2019)
mwg-biotech uk limited (January 2007)
accountant
-
auditor
CONSTANTIN
address
i54 busines park, valiant way, wolverhampton, WV9 5GB
Bank
HSBC BANK PLC
Legal Advisor
-
eurofins genomics uk limited Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We did not find charges/mortgages relating to eurofins genomics uk limited.
eurofins genomics uk limited Capital Raised & Share Issues BETA
When a company issues new shares, e.g. to new investors following a funding round, it is required to notify Companies House within one month of making an allotment of shares.
Click to start generating capital raising & share issue transactions for EUROFINS GENOMICS UK LIMITED. This can take several minutes, an email will notify you when this has completed.
eurofins genomics uk limited Companies House Filings - See Documents
| date | description | view/download |
|---|
